INJ Soars 15% as EVM Testnet Goes Live—Strategic Partnerships Fuel Bullish Momentum

Injective (INJ) just ripped past resistance with a 15% surge—EVM compatibility hits testnet, and Wall Street's flirting with crypto again (until the next 'risk-off' tantrum, anyway).

Why the pump? Three words: execution meets hype. The team dropped an Ethereum Virtual Machine (EVM) testnet this week, opening floodgates for Solidity devs to port dApps without rewriting code. Meanwhile, backchannel deals with institutional liquidity providers suggest TradFi's warming up to INJ's orderbook-centric DeFi model.

Partnerships? Check. LayerZero integration went live last quarter, and whispers point to a CME Group sandbox trial—because nothing screams decentralization like Chicago's mercantile old guard testing the waters.

Price action? INJ's eating supply zones for breakfast. The 15% pop puts it within striking distance of its Q1 highs, though chartists note weakening volume. Bulls argue this is accumulation; skeptics see overleveraged degens chasing the next 'institutional adoption' narrative.

Bottom line: Injective's delivering infrastructure while rivals tweet memes. Just don't expect hedge funds to care when Bitcoin inevitably drags the altcoin market through another liquidity wringer.

Injective Protocol (INJ) has experienced a bullish surge over the past week, driven by a series of impactful developments. These include the launch of its EVM testnet, strategic partnerships with tech giants Google Cloud and Deutsche Telekom, and a significant increase in on-chain activity. The platform's focus on real-world asset (RWA) tokenization and institutional integration has positioned it as a leader in decentralized finance (DeFi). With INJ trading at $12.88, technical indicators suggest further potential upside, though market volatility remains a consideration.

The past week has been monumental for Injective, with several key events shaping market sentiment:

• EVM Testnet Launch and Partnerships (July 13, 2025):
  Injective's EVM testnet launch marked a significant milestone, enhancing compatibility with Ethereum-based assets. This development aligns with the platform’s push for RWA tokenization. Strategic partnerships with Google Cloud and Deutsche Telekom further validated Injective's institutional appeal, driving a 15% price surge and boosting daily active addresses by 1,700% since January.

• Formation of the Injective Council (July 12, 2025):
  The newly established Injective Council includes leaders from top-tier organizations like BitGo, Galaxy, and NTT Digital. This move aims to accelerate institutional adoption and DeFi innovation, with INJ gaining 27% over the week, closing at $12.75 on July 12.

• Increased Whale Activity (July 12, 2025):
  Whale activity and strong volume contributed to INJ's bullish momentum, breaking a multi-month downtrend. Analysts are now eyeing resistance levels at $14.16 and $15.43.

• Market Trends and Technical Signals (July 9, 2025):
  Despite a slight price dip earlier in the week, Injective's fundamentals remain strong. Total Value Locked (TVL) rose by 65% since April, reflecting growing interest in its DeFi solutions.

These developments underscore Injective's growing dominance in the DeFi space, positioning it as a key player in global blockchain adoption.

As of July 14, 2025, Injective's technical indicators reveal a weak bullish trend with potential for further gains:

• Current Price: $12.88
• 24h Change: +1.90%
• Resistance Levels: $13.16, $15.48
• Support Levels: $10.07, $8.95

- SMA7: $11.92
- SMA20: $11.22
- SMA50: $11.83
- SMA200: $13.23

The price trading above short-term moving averages indicates bullish momentum. However, the 200-day SMA serves as a critical resistance point.

-62.30 (approaching overbought territory)
-0.2726 (bullish crossover)
-%K at 90.94, signaling overbought conditions

- Upper: $12.76
- Lower: $9.68
- %B: 1.0376 (indicating strong upward pressure)

The technical outlook suggests cautious optimism, with a focus on breaking the $13.16 resistance.

- Consider entering long positions if INJ consolidates above $13.16, targeting $14.16 and $15.43.
- Monitor RSI and Stochastic levels for signs of overbought conditions to avoid potential pullbacks.

- Place stop-loss orders below $10.07 to mitigate downside risks.

- The 24h trading volume of $15.28 million reflects strong investor interest, supporting further price appreciation.

Given the recent EVM testnet launch and strategic partnerships, Injective is poised for sustained growth. Analysts project the following price targets:
-$14.16 (Resistance 1)
-$15.48 (Resistance 2)

However, failure to sustain momentum could see prices retest support levels at $10.07 or lower.

While the outlook for Injective is bullish, traders should consider the following risks:
-Sudden macroeconomic changes or negative crypto market sentiment could impact INJ prices.
-Momentum indicators, such as RSI and Stochastic Oscillator, suggest the possibility of short-term corrections.
-A failure to break this level may limit upward momentum.

Injective Protocol (INJ) has emerged as a leading DeFi platform, bolstered by its EVM testnet launch, growing institutional partnerships, and increased on-chain activity. While technical indicators point to bullish potential, traders should remain cautious of overbought conditions and resistance levels. With its focus on innovation and global adoption, Injective is well-positioned for long-term success in the competitive DeFi landscape.

• inj price analysis
• inj price prediction